<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922853</url>
  </required_header>
  <id_info>
    <org_study_id>RC-CT-2021</org_study_id>
    <nct_id>NCT04922853</nct_id>
  </id_info>
  <brief_title>Comparison of the Pathological Effect Between 2 Cycles and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate RC</brief_title>
  <official_title>Comparison of the Pathological Effect Between 2 Cycles and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk Rectal Cancer: a Prospective, Non-inferior, Multiple Centers, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Third Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Chengdu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Fifth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as&#xD;
      neoadjuvant chemotherapy for low/ intermediate risk stage II/III rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neoadjuvant Chemotherapy alone has showed much benefit for low/ intermediate risk stage&#xD;
      II/III rectal cancer which would be verified by the PROSPECT trial. However, the effect of&#xD;
      the Neoadjuvant chemotherapy was heterogeneous in different patients. It's important to&#xD;
      verify those chemo-resistant cases as early as possible. So that, this trial will compare the&#xD;
      pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant&#xD;
      chemotherapy for low/ intermediate risk stage II/III rectal cancer to explore whether those&#xD;
      chemotherapeutic non-responders after 2 cycles Capox was non-inferior to those after 4 cycles&#xD;
      chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 26, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological Tumor Regression Grade evaluation</measure>
    <time_frame>12 weeks</time_frame>
    <description>pTRG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of chemotherapeutic complication</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 year after recruiting</time_frame>
    <description>the cumulative overall survival rate of the patients(events defined as all caused death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 year after recruiting</time_frame>
    <description>the cumulative disease free survival rate of the patients(events defined as tumor recurrence at any sites)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative distant recurrence rate</measure>
    <time_frame>3 year after recruiting</time_frame>
    <description>cumulative recurrence rate of Rectal cancer after the radical surgery outside the pelvic cavity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative local recurrence rate</measure>
    <time_frame>3 year after recruiting</time_frame>
    <description>cumulative recurrence rate of Rectal cancer after the radical surgery within the pelvic cavity or in the wounds</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">562</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>2 cycles group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have TME operation after reevaluation and randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 cycles group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have two more cycles chemotherapy and TME operation after reevaluation and randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capox chemotherapy</intervention_name>
    <description>oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals</description>
    <arm_group_label>2 cycles group</arm_group_label>
    <arm_group_label>4 cycles group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-75 years old; No gender limitation;&#xD;
&#xD;
          2. Patients diagnosed with low/intermediate risk stage II/III rectal cancer under MRI and&#xD;
             transanal ultrasound,defined as: low:T3a-bN0-1M0, EMVI (±), MRF (-) (≥2mm);&#xD;
             Middle-high rectal cancer: T3a-cN0-1M0, EMVI (±), MRF (-) (≥2mm); No more than 3 lymph&#xD;
             nodes with short diameter over 8mm or highly suspected metastases; Patients with very&#xD;
             low rectal cancer who met the above criteria and could achieve negative&#xD;
             circumferential resection margin under ELAPE surgery could be included in the group&#xD;
&#xD;
          3. tumor located &lt;=12cm from anal verge by colonoscopy or anal examination&#xD;
&#xD;
          4. no distant metastasis confirmed by CT examination;&#xD;
&#xD;
          5. rectal adenocarcinoma confirmed by pathology,&#xD;
&#xD;
          6. ECOG score: 0-1;&#xD;
&#xD;
          7. Patients with primary rectal cancer who did not receive surgery (except palliative&#xD;
             stomy), radiotherapy, systemic chemotherapy or other anti-tumor therapy before&#xD;
             enrollment;&#xD;
&#xD;
          8. Main organs function normally, that is, meet the following characteristics: ① Blood&#xD;
             routine examination criteria should meet: Hb ≥9g/dL, WBC ≥ 3.5/4.0×109/L, neutrophils&#xD;
             ≥ 1.5×109/L, PLT≥ 100×109/L. ② Biochemical tests should meet the following criteria:&#xD;
             CREA and BIL ≤ 1.0 times upper limit of normal (ULN), ALT and AST≤ 2.5 times upper&#xD;
             limit of normal (ULN), alkaline phosphatase (ALP) ≤2.5×UNL, total bilirubin (TBIL)&#xD;
             ≤1.5×UNL.&#xD;
&#xD;
          9. No history of allergy to platinum drugs when no 5-FU drugs are allergic;&#xD;
&#xD;
         10. Women of childbearing age must have had a pregnancy test (serum or urine) 7 days prior&#xD;
             to enrolment, be negative, and be willing to use an appropriate method of&#xD;
             contraception during the trial and 8 weeks after the last dosing. For men, surgical&#xD;
             sterilization or consent to use an appropriate method of contraception during the&#xD;
             trial or for 8 weeks after the last dosing;&#xD;
&#xD;
         11. Subjects volunteered to participate in this study, signed the informed consent, and&#xD;
             showed good compliance and followed up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients suspect to Lynch syndrome;&#xD;
&#xD;
          2. Patients showed distant metastasis during treatment;&#xD;
&#xD;
          3. Previously or coexisting malignancies (including concurrent colon cancer), except for&#xD;
             cured basal cell carcinoma of the skin and carcinoma in situ of the cervix;&#xD;
&#xD;
          4. pregnant or breastfeeding women;&#xD;
&#xD;
          5. Patients with severe cardiovascular diseases and diabetes that is not easily&#xD;
             controlled;&#xD;
&#xD;
          6. People with mental disorders;&#xD;
&#xD;
          7. Severe infection;&#xD;
&#xD;
          8. sever renal disfunction;&#xD;
&#xD;
          9. History of gastrointestinal fistula, perforation, bleeding, or severe ulcer;&#xD;
&#xD;
         10. Allergic to 5-FU or platinum;&#xD;
&#xD;
         11. The presence of serious gastrointestinal diseases that affect the absorption of oral&#xD;
             chemotherapeutic drugs; (12) Participants in additional clinical trials within 4 weeks&#xD;
             prior to the start of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ziqiang Wang, MD</last_name>
    <phone>18980602028</phone>
    <email>wangziqiang@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiangbing Deng, MD</last_name>
    <phone>13730677124</phone>
    <email>247940362@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the Third People'S Hospital of Chengdu</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Yan jun, MD</last_name>
      <phone>15108402860</phone>
    </contact>
    <investigator>
      <last_name>Liu Yan jun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziqiang Wang, MD</last_name>
      <phone>18980602028</phone>
      <email>wangziqiang@scu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Mingtian Wei, MD</last_name>
      <phone>18980602400</phone>
    </contact_backup>
    <investigator>
      <last_name>Ziqiang Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Liu, MD</last_name>
      <phone>+8615911552189</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Ziqiang Wang,MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

